Kathryn Packman
Overview
Explore the profile of Kathryn Packman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K, et al.
iScience
. 2025 Mar;
28(3):111876.
PMID: 40060890
T cell-redirecting bispecific antibodies (bsAbs) to treat advanced stage solid tumors are gaining interest after recent clinical successes. The immune checkpoint human leukocyte antigen G (HLA-G) is expressed in several...
2.
Mattson Cypert B, Menard K, Chu G, McDevitt T, Verona R, Rupnow B, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 40008870
Prostate cancer is considered immunologically "cold", with low mutational burden, tumor-infiltrating immune cells, and PD-L1 levels, culminating in poor response to immune checkpoint therapies. Bispecific CD3 redirection antibodies can elicit...
3.
Kwon M, Thuring J, Querolle O, Dai X, Verhulst T, Pande V, et al.
Blood
. 2024 Jun;
144(11):1206-1220.
PMID: 38905635
The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)-altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is...
4.
Guerlavais V, Sawyer T, Carvajal L, Chang Y, Graves B, Ren J, et al.
J Med Chem
. 2023 Jul;
66(14):9401-9417.
PMID: 37439511
We report the discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide to enter clinical trials. ALRN-6924 is a "stapled peptide" that mimics the N-terminal domain of the p53...
5.
Mamai A, Chau A, Wilson B, Watson I, Joseph B, Subramanian P, et al.
ACS Med Chem Lett
. 2023 Feb;
14(2):199-210.
PMID: 36793435
B cell lymphoma 6 (BCL6), a highly regulated transcriptional repressor, is deregulated in several forms of non-Hodgkin lymphoma (NHL), most notably in diffuse large B-cell lymphoma (DLBCL). The activities of...
6.
Tichenor M, Wiener J, Rao N, Bacani G, Wei J, Pooley Deckhut C, et al.
J Med Chem
. 2022 Oct;
65(21):14326-14336.
PMID: 36314537
Bruton's tyrosine kinase (BTK) is a Tec family kinase that plays an essential role in B-cell receptor (BCR) signaling as well as Fcγ receptor signaling in leukocytes. Pharmacological inhibition of...
7.
Snyder L, Damle R, Patel S, Bohrer J, Fiorella A, Driscoll J, et al.
Mol Cancer Ther
. 2022 May;
21(7):1115-1124.
PMID: 35499386
Patients with prostate cancer whose tumors bear deleterious mutations in DNA-repair pathways often respond to PARP inhibitors. Studies were conducted to compare the activity of several PARP inhibitors in vitro...
8.
DeAngelis N, Ferrante C, Powers G, Sendecki J, Mattson B, Pizutti D, et al.
Cancer Chemother Pharmacol
. 2022 Mar;
89(4):515-527.
PMID: 35298699
Purpose: Preclinical characterization of cetrelimab (JNJ-63723283), a fully humanized immunoglobulin G4 kappa monoclonal antibody targeting programmed cell death protein-1 (PD-1), in human cancer models. Methods: Cetrelimab was generated by phage...
9.
Brehmer D, Beke L, Wu T, Millar H, Moy C, Sun W, et al.
Mol Cancer Ther
. 2021 Sep;
20(12):2317-2328.
PMID: 34583982
The protein arginine methyltransferase 5 (PRMT5) methylates a variety of proteins involved in splicing, multiple signal transduction pathways, epigenetic control of gene expression, and mechanisms leading to protein expression required...
10.
Branch J, Bush T, Pande V, Connolly P, Zhang Z, Hickson I, et al.
Mol Cancer Ther
. 2021 Mar;
20(5):763-774.
PMID: 33649102
Numerous mechanisms of resistance arise in response to treatment with second-generation androgen receptor (AR) pathway inhibitors in metastatic castration-resistant prostate cancer (mCRPC). Among these, point mutations in the ligand binding...